Neuromeka Decides on 126.6B KRW Rights Offering at 39,600 KRW per Share... Largest Shareholder Stake May Drop to 14.67%, Raising Dilution Concerns
Neuromeka has finalized a rights offering of 3,196,465 new shares (25.76% of outstanding) at 39,600 KRW per share, raising approximately 126.6 billion KRW (net 125.4 billion KRW after expenses).
Proceeds will be used for: 80 billion KRW for new factory construction in Pohang, 36.6 billion KRW for working capital (raw materials, R&D hiring, factory stabilization), and 10 billion KRW for short-term debt repayment. The working capital plan was reduced from 60 billion to 36.6 billion KRW; 2029-2030 needs will be funded from operating cash flow.
CEO and largest shareholder Park Jong-hoon plans to subscribe to only ~15% of his allotment (85,343 of 568,955 shares) and may sell 70,000 existing shares and the remaining rights via block deal to fund the subscription. His stake is expected to drop from 17.80% to 14.25% (from 18.33% to 14.67% including related parties).
Existing convertible bonds (1st and 2nd series) will see conversion prices adjusted downward due to the offering discount (1st: 30,867→29,360 KRW, 2nd: 23,892→22,726 KRW), and further after the 50% stock dividend (1st: 19,574 KRW, 2nd: 15,151 KRW), potentially increasing convertible shares to 631,215. Outstanding stock options will also adjust to 86,215 shares post-stock dividend.
A 50% stock dividend (7,802,808 shares) will follow the rights offering, funded from paid-in capital in excess of par value. The stock dividend applies to both existing and newly issued shares from the rights offering.
The company reported 2025 consolidated revenue of 19.0 billion KRW, operating loss of 14.9 billion KRW, and net loss of 22.0 billion KRW, marking three consecutive years of significant losses. In Q1 2026, a net loss of 25.7 billion KRW occurred, mainly due to a non-cash bond conversion loss (22.6 billion KRW).
Pro forma after the offering, the debt ratio improves from 101% (Q1 2026) to 18.84%, and the current ratio from 90.53% to 622.24%. However, continued operating losses could erode these improvements.
The company is pursuing Physical AI commercialization, KCs safety certification for its humanoid robot EIR (target H1 2026), and expansion of collaborative robots and automation solutions. However, risks include technology validation delays and intensifying global competition.
[AI Summary]Neuromeka's 126.6 billion KRW rights offering will dilute existing shareholders by 25.76%, and the low participation of the largest shareholder (15%) may weaken control. The funds are earmarked for capacity expansion and improving financials, but the company's three-year streak of heavy operating losses and negative cash flow poses a significant risk. Until Physical AI and humanoid robot commercialization yields tangible results, the stock is likely to face continued downward pressure.
KOSDAQ Filing Information
Filing: [Correction of Description] Securities Registration Statement (Equity Securities)